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In this study, conditions were optimized for development of a simple RP-HPLC method for simultaneous 
analysis of gatifloxacin and dexamethasone in different matrices like pharmaceuticals, human serum 
and urine. Good separation of gatifloxacin and dexamethasone from the induced degradation products 
was accomplished using C8 as stationary phase; 0.02 M phosphate buffer (pH 3.0) and methanol (42:58 
v/v) as mobile phase. The concentration was measured with DAD at 270 nm. Linearity was observed 
in the range of 0.000040-0.000280 mol/L for gatifloxacin (r2≥0.999) and 0.000013-0.000091 mol/L 
for dexamethasone (r2≥0.999). Both the analyte peaks were completely separated from the peaks of 
induced degradation products as indicated by the peak purity index (≥0.9999 for both analytes). The 
optimized method is recommended to be used for concurrent analysis of gatifloxacin and dexamethasone 
in different matrices.
Uniterms: Gatifloxacin. Dexamethasone. High performance liquid chromatography. Validation. Plasma. 
Degradation products.
INTRODUCTION
Gatifloxacin (Figure 1A), a broad spectrum 
antibiotic is primarily used to treat bacterial infections 
like conjunctivitis, keratitis, pre and post-operative 
(Martindale, 2009). Dexamethasone (Figure 1B), a 
corticosteroid, used primarily for ocular inflammation 
conditions and where the risk of bacterial ocular 
infection or its risk is found (Martindale, 2009). 
The determination of gatifloxacin has widely been 
reported using spectrophotometry (Sonali et al., 2006; 
Venugopal, Ranendra, 2005), HPLC (Santoro et al., 2006), 
atomic absorption spectrophotometry, conductometry, 
colorimetry (Sheikh, 2008) and spectrofluorimetry 
(Ocaña, Barragán, Callejón, 2005). Similarly, the 
estimation of dexamethasone has also been reported 
widely by HPLC (Iqbal et al., 2006; Huetos et al., 1999; 
Mallinson et al., 1995; Chen et al., 2008; Lemus Gallego, 
Pérez Arroyo, 2002; Cocenza, Mainardes, Gremião, 2009; 
Kwak, D’Amico, 1995), GC-MS (Mallinson et al., 1995) 
and TLC (Huetos et al., 1999).
Although gatifloxacin and dexamethasone fixed 
dose combination (FDC) is available for sale, however 
not officially adopted by any pharmacopeia. Scientific 
literature was also found scarce of any stability indicating 
method for this FDC. In order to fill this knowledge 
FIGURE 1 - Chemical Structures of gatifloxacin (A) and 
dexamethasone (B).
S. N. Razzaq, M. Ashfaq, I. U. Khan, I. Mariam, S. S. Razzaq, G. Mustafa, M. Zubair
Braz. J. Pharm. Sci. 2017;53(1):e15177Page 2 / 8
gap, the present study was designed to optimize the 
chromatographic conditions in order to estimate them in 
different matrices (pharmaceutical formulations, human 
urine and serum). In the past few years, different FDC 
have already been reported by our research group after 
developing suitable analytical methods (Ashfaq et al., 
2013; 2014; Khan et al., 2013; 2014; Razzaq et al., 2013; 
2014; John et al., 2015a, b; Saleem et al., 2015).
MATERIAL AND METHODS
Chemicals and Reagents 
Gatifloxacin (99.7%) and dexamethasone (99.2%) 
reference standards were obtained as gift samples from 
a pharmaceutical laboratory located at Lahore, Pakistan. 
GATE DX and GATIBLU-D ophthalmic preparations (3 
mg/mL gatifloxacin and 1 mg/mL dexamethasone) were 
analyzed during the applications of the method. All other 
chemicals and reagents were of highest analytical grades 
available in the market. For filtration of all solutions 
including mobile phase, 0.45 µm nylon filters (Millipore, 
USA) were used. 
Equipment and Chromatographic Conditions
Liquid chromatography as well as integration 
of peak areas and chromatographic parameter were 
calculated using Shimadzu LC-20A system (Kyoto, 
Japan) at 270 nm. Hypersil C8 column (0.250 m X 4.6 
mm, 5 mm) was used as stationary phase while 0.02 M 
phosphate buffer pH 3.0 (adjusted by 1 mL triethylamine 
and phosphoric acid) and methanol (42:58 v/v) were used 
as mobile phase at 1.5 mL/min. 
Preparation of Standard Solution (A) and Working 
Standard Solution (B)
Stock solution (A) of gatifloxacin (0.0040 mol/L) 
and dexamethasone (0.00130 mol/L) was prepared by 
dissolving 150 mg gatifloxacin and 50 mg dexamethasone 
in few mL of methanol in 100 mL measuring flask, 
sonicated for few minutes and then diluted up to the mark 
with mobile phase. Solution was then subsequently diluted 
to get working solution (B) of gatifloxacin (0.000160 
mol/L) and dexamethasone (0.000052 mol/L). 
Preparation of Sample Solution
An appropriate volume of commercial ophthalmic 
solut ion was di luted with  mobi le  phase to  get 
0.000160 mol/L gatifloxacin and 0.000052 mol/L 
dexamethasone. 
Preparation of Human Urine Samples 
1250 µL of solution A was mixed with equal 
volume of human urine for 2 minutes, followed by its 
centrifugation for 10 minutes at 4000 rpm. The supernatant 
(200 µL) was added in 2300 µL of the mobile phase. The 
final concentration of solution thus obtained was equal to 
(0.000160 mol/L of gatifloxacin and 0.000052 mol/L of 
dexamethasone).
Preparation of Human Serum Samples
Solucion A, 50 µL, was mixed with 250 µL human 
serum, followed by adding 950 µL mobile phase. The 
mixture was centrifuged for 10 minutes at 4000 rpm and 
the supernatant was shifted in polypropylene tubes having 
concentration equal to 0.000160 mol/L for gatifloxacin and 
0.000052 mol/L for dexamethasone.
Linearity
Linearity was established by analyzing each solution 
in triplicate in the range of 0.000040-0.000280 mol/L 
(0.000040, 0.000080, 0.000120, 0.000160, 0.000200, 
0.000240 and 0.000280 mol/L) of gatifloxacin and 
0.000013-0.000091 mol/L of dexamethasone (0.000013, 
0.000026, 0.000039, 0.000052, 0.000065, 0.000078 and 
0.000091 mol/L).
Accuracy
Synthetic mixtures of both analytes were analyzed 
in order to evaluate accuracy. The synthetic mixture was 
prepared by mixing appropriate amounts of gatifloxacin, 
dexamethasone, benzalkonium chloride and sodium 
chloride in 1L purified water. The solution was then 
diluted to get solutions of three different concentrations 
(50-150%) of working solution concentration (0.000160 
mol/L gatifloxacin and 0.000052 mol/L dexamethasone). 
These solutions were further used to test recovery studies.
Precision
Precision was evaluated by calculating % RSD 
of the samples analyzed within one day for five times 
and for sample analyzed for three days. Three different 
concentration of solutions were used for both within-day 
and between-day precision.
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Specificity (Stress Testing)
Acid Degradation Studies
To four separate measuring flasks, each contained 1 
mL solution A, 5 M hydrochloric acid (1 mL) was mixed 
and kept in chamber at 40 oC/75% RH for 1, 8, 16 and 23 
h followed by neutralization and completing to the mark. 
Base, Oxidative and Thermal Degradation Studies
Same procedure was used for base, oxidative and 
thermal stress studies except using 5 M NaOH instead of 5 
M HCl in basic stress, 6% H2O2 for oxidative stress (1, 8,23 
and 70 h) and 1, 16, 24 and 70 h time for thermal stress.
Photolytic Degradation Studies 
Three separate 25 mL measuring flasks containing 
1 mL of solution A were exposed to direct sunlight for 2, 
4 and 6 h, followed by marking the volume.
RESULTS AND DISCUSSION 
Reverse phase (RP) chromatography has been used 
widely in the last two decades for the separation of many 
organic molecules particularly pharmaceuticals because of 
containing major non-polar groups as well as containing 
unsaturated π electrons. As both the investigating 
pharmaceuticals have this common feature in their 
structure, so in this study, an RP-HPLC was developed for 
simultaneous analysis of gatifloxacin and dexamethasone 
in different matrices like pharmaceuticals, human serum 
and urine. 
Optimization of Mobile Phase and Stationary 
Phase
Both dexamethasone and gatifloxacin have been 
analyzed individually in previous methods (Razzaq et 
al., 2013; 2014; Khan et al., 2014). In order to develop a 
method that can quantify both of these simultaneously, 
we took advantage of the problems faced during the 
previous studies, where dexamethasone peak showed 
high tailing on C18, Phenyl-2, and Cyano columns but 
symmetrical/good peak on C8 (Razzaq et al., 2013; 2014; 
Khan et al., 2014). So we chose C8 column for this FDC. 
Some minor changes in the composition of organic and 
aqueous phase as well as pH were good enough to resolve 
both these compounds from each other as well as from 
induced degradation products. The final composition of 
the mobile phase thus used was, methanol: phosphate 
buffer 0.02 M, pH 3.0 (58:42, v/v) that resulted in good/
symmetrical peaks. 
Analytical Method Validation
Validation parameters like linearity, accuracy, 
precision, robustness, specificity, limit of detection and 
quantitation as recommended by ICH (International 
Conference on Harmonization, 1996) were evaluated 
when validating this method.
Linearity was established by analyzing each solution 
in triplicate in the range of 0.000040-0.000280 mol/L 
(0.000040, 0.000080, 0.000120, 0.000160, 0.000200, 
0.000240 and 0.000280 mol/L) of gatifloxacin and 
0.000013-0.000091 mol/L of dexamethasone (0.000013, 
0.000026, 0.000039, 0.000052, 0.000065, 0.000078 and 
0.000091 mol/L). The linear regression equation for 
gatifloxacin was found to be Y= 46312 X + 4983 with 
correlation coefficient ≥0.999 whereas for dexamethasone 
it was Y= 94196 X + 1566 with correlation coefficient 
≥0.999.
Limit of detection (LOD) was found to be 0.0000008 
mol/L and 0.0000003 mol/L (Figure 3) for gatifloxacin 
and dexamethasone, respectively (Figure 6). LOQ was 
found to be 0.0000027 mol/L and 0.0000001 mol/L for 
gatifloxacin and dexamethasone, respectively.
Synthet ic  mixtures  of  both analytes  were 
analyzed to evaluate accuracy. Solutions of three 
different concentrations (50-150%) of working solution 
concentration (0.000160 mol/L gatifloxacin and 
0.000052 mol/L dexamethasone) were used to test 
recovery. The results are presented in (Table I), indicating 
good recovery.
Precision was evaluated by calculating % RSD 
of the samples analyzed within one day for five times 
and for sample analyzed for three days. Three different 
concentration of solutions were used for both within-day 
and between-day precision. The results are presented in 
(Table II).
Slight variation in the chromatographic conditions 
were made in order to evaluate robustness. Results 
presented in (Table III and Table IV) showed little effect 
on chromatographic parameters.
The chromatograms involving forced stresses 
are shown in (Figure 2), whereas the results describing 
percentage degradation and extent of degradation are 
provided (Table V).
Both the drugs were degraded with ease under most 
of the stress conditions (except thermal and oxidative). 
When comparing the vulnerability of both drugs, it 
was observed that dexamethasone was easy to degrade 
compared to gatifloxacin (31% and 95 % degradation 
under acidic and basic conditions). Up to 4 degradation 
products were observed during the mentioned stresses.
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TABLE I - Accuracy of the proposed HPLC method
Nature of Sample Spiked Concentrations mol/L
Measured Concentration 
mol/L ± RSD (%) Recovery (%)
Pharmaceutical Formulations
Gatifloxacin
0.000080 0.0000806 ± 1.19 100.7
0.000160 0.000160 ± 0.41 100.0
0.000240 0.0002431 ± 0.91 101.3
Dexamethasone
0.000026 0.0000259 ± 0.49 99.50
0.000052 0.0000523 ± 1.24 100.5
0.000078 0.0000785 ± 0.61 100.7
Spiked Serum
Gatifloxacin
0.000080 0.000072 ± 1.65 90.0
0.000160 0.000147 ± 3.24 91.9
0.000240 0.000219 ± 1.33 91.4
Dexamethasone
0.000026 0.0000258 ± 1.39 99.2
0.000052 0.0000525 ± 1.93 100.9
0.000078 0.000079 ± 1.90 101.3
Spiked Urine
Gatifloxacin
0.000080 0.0000796 ± 1.14 99.5
0.000160 0.000163 ± 0.68 101.8
0.000240 0.000244 ± 1.79 101.5
Dexamethasone
0.000026 0.0000261 ± 1.94 100.2
0.000052 0.0000523 ± 1.61 100.5
0.000078 0.0000782 ± 1.31 100.3
TABLE II - Intra-Day and Inter-Day precision of the proposed HPLC method
Drugs Actual Concentration mol/L
Intra-Day Precision 
Measured Concentration 
mol/L ± RSD (%)
Inter-Day precision 
Measured Concentration 
mol/L ± RSD (%)
Pharmaceutical Formulations
Gatifloxacin
0.000080 0.0000783 ± 1.21 0.0000803 ± 1.87
0.000160 0.0001614 ± 1.92 0.0001627 ± 0.99
0.000240 0.0002400 ± 0.81 0.0002406 ± 0.82
Dexamethasone
0.000026 0.0000262 ± 1.87 0.0000260 ± 1.41
0.000052 0.0000525 ± 0.51 0.0000526 ± 1.89
0.000078 0.0000780 ± 1.22 0.0000777 ± 1.20
Spiked Serum
Gatifloxacin
0.000080 0.0000767 ± 1.58 0.0000758 ± 2.26
0.000160 0.0001471 ± 2.99 0.0001511 ± 2.94
0.000240 0.0002252 ± 1.10 0.0002205 ± 2.09
Dexamethasone
0.000026 0.0000260 ± 1.15 0.0000261 ± 2.14
0.000052 0.0000526 ± 2.17 0.0000520 ± 2.43
0.000078 0.0000780 ± 1.95 0.0000782 ± 1.18
Spiked Urine
Gatifloxacin
0.000080 0.0000797 ± 1.54 0.0000804 ± 2.16
0.000160 0.0001623 ± 1.08 0.0001647 ± 1.04
0.000240 0.0002402 ± 1.54 0.0002406 ± 1.72
Dexamethasone
0.000026 0.0000262 ± 1.08 0.0000262 ± 1.54
0.000052 0.0000523 ± 1.53 0.0000525 ± 1.13
0.000078 0.0000781 ± 1.29 0.0000776 ± 1.34
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The developed method was finally used to determine 
gatifloxacin and dexamethasone in commercially available 
ophthalmic solutions (Table VI), spiked human serum and 
urine (Figure 3). Excellent results were obtained from 
these experiments.
CONCLUSION
In this study, an RP-HPLC method was developed for 
simultaneous analysis of gatifloxacin and dexamethasone 
in different matrices like pharmaceuticals, human 
serum and urine. Method validation was performed 
as recommended by ICH. The optimized method is 
recommended to be used for concurrent analysis of 
gatifloxacin and dexamethasone in different matrices 
because of its excellent results with inexpensive reagents.
TABLE III - Robustness study of Gatifloxacin
Chromatographic conditions Assay (%) tR (min) Plates Tailing
Methanol: buffer (61:39) 98.7 2.99 4507 1.42
Methanol: buffer (58:42) 100.6 3.38 4588 1.41
Methanol: buffer (55:45) 100.9 3.69 4478 1.44
Flow rate (1.3 mL/min) 100.9 3.75 4601 1.43
Flow rate (1.5 mL/min) 99.8 3.38 4577 1.43
Flow rate (1.7 mL/min) 100.5 2.89 4587 1.41
Buffer (pH 2.8) 102.0 3.34 4691 1.44
Buffer (pH 3.0) 101.5 3.38 4511 1.41
Buffer (pH 3.2) 99.6 3.38 4547 1.40
TABLE IV - Robustness study of Dexamethasone
Chromatographic conditions Assay (%) tR (min) Plates Tailing
Methanol: buffer (61:39) 101.7 7.52 6821 1.20
Methanol: buffer (58:42) 100.9 7.75 6799 1.21
Methanol: buffer (55:45) 100.0 7.92 6647 1.21
Flow rate (1.3 mL/min) 99.9 9.19 6788 1.20
Flow rate (1.5 mL/min) 99.9 7.75 6718 1.22
Flow rate (1.7 mL/min) 99.5 6.82 6895 1.23
Buffer (pH 2.8) 100.7 7.75 6805 1.22
Buffer (pH 3.0) 98.7 7.77 6705 1.24
Buffer (pH 3.2) 100.7 7.74 6611 1.22
FIGURE 2 - A typical chromatogram of gatifloxacin and 
dexamethasone under acidic, basic, thermal, photolytic and 
oxidative stress conditions. Where (X) is gatifloxacin peak, 
(Y) is dexamethasone peak, (1, 2, 3, and 4) are degradation/
impurities peaks, (A) chromatogram of basic stress, (B) 
chromatogram of thermal stress, (C) chromatogram of 
acidic stress, (D) chromatogram of photolytic stress and (E) 
chromatogram of oxidative stress.
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TABLE V - Stress testing results of gatifloxacin and dexamethasone
Nature of stress Storage condition (°C/%RH) Time (h)
Amount of 
gatifloxacin 
remaining ± RSD 
(%)
Amount of 
dexamethasone 
remaining ± RSD 
(%)
Extent of 
decomposition
5 M HCl (40/75) 1 100.1 ± 1.2 101.3 ± 0.30 None
(40 /75) 8 99.7 ± 1.0 97.6 ± 1.1 None
(40/75) 16 97.2 ± 0.80 90.0 ± 1.5 Slight
(40/75) 23 100.3 ± 0.90 68.6 ± 1.2 Substantial
5 M NaOH (40/75) 16 93.7 ± 1.7 4.8 ± 2.3 Substantial
6% H2O2 (40/75) 1 98.6 ± 1.5 100.8 ± 1.5 None
(40/75 ) 8 101.2 ± 1.4 100.5 ± 1.4 None
(40/75) 23 95.5 ± 1.4 100.6 ± 1.5 None
(40/75 70 96.8 ± 1.1 96.7 ± 1.9 None
Thermal (40/75 ) 1 100.3 ± 0.80 99.5 ± 1.5 None
(40/75) 16 99.7 ± 0.40 100.4 ± 1.4 None
(40/75) 24 100.0 ± 1.3 102.8 ± 1.5 None
(40/75 ) 70 98.5 ± 1.0 93.2 ± 1.7 None
Photolytic Sunlight 2 99.8 ± 1.9 102.9 ± 1.2 None
Sunlight 4 98.6 ± 1.4 102.3 ± 1.4 None
Sunlight 6 91.3 ± 1.9 78.4 ± 1.4 Substantial
TABLE VI - Assay results of gatifloxacin and dexamethasone in commercial eye drops
Product Ingredient Label value (mg/mL) Recovery (%) ± RSD (%)
GATE DX gatifloxacin 3 100.3 ± 0.30
dexamethasone 1 99.00 ± 0.70
GATIBLU-D gatifloxacin 3 100.7 ± 0.10
dexamethasone 1 98.90 ± 0.70
FIGURE 3 - Chromatograms of gatifloxacin and dexamethasone in Pharmaceutical Formulations (A), Human Serum (B) and 
Urine (C).
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